![MabThera 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc) MabThera 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~2570~54~image3.png)
MabThera 500 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)
![Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes - ScienceDirect Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253819310476-fx1.jpg)
Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes - ScienceDirect
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma | Haematologica
![783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ 783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ](https://www.eviq.org.au/getmedia/697d4ac9-e60a-4f9c-8492-1097b4f25eb0/Alliance-CALGB-50303-Bartlett-Fig-2.png.aspx)
783-DA-R-EPOCH (dose adjusted rituximab etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXO | eviQ
![Modified Rheumatoid Arthritis Protocol for Rituximab in Pemphigus: A Retrospective Case Series – JCAD | The Journal of Clinical and Aesthetic Dermatology Modified Rheumatoid Arthritis Protocol for Rituximab in Pemphigus: A Retrospective Case Series – JCAD | The Journal of Clinical and Aesthetic Dermatology](https://jcadonline.com/wp-content/uploads/SakhiyaTable1.gif)